Von Hippel-Lindau syndrome (VHL) is a dominantly inherited familial cancer syndrome predisposing to a variety of malignant and benign tumors. A germline mutation of VHL gene is the basis of familial inheritance of VHL syndrome. The protein is a component of the protein complex that includes elongin B, elongin C, and cullin-2, and possesses ubiquitin ligase E3 activity. This protein is involved in the ubiquitination and degradation of hypoxia-inducible-factor (HIF), which is a transcription factor that plays a central role in the regulation of gene expression by oxygen. RNA polymerase II subunit POLR2G/RPB7 is also reported to be a target of this protein.

Titration of the VHL antibody may be required due to differences in protocols and secondary/substrate sensitivity.

A portion of amino acids 43-71 from the human protein was used as the immunogen for this VHL antibody.

Aliquot the VHL antibody and store frozen at -20oC or colder.Avoid repeated freeze-thaw cycles.